Certara

37 articles with Certara

• Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

  6/28/2022

  Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research.

• Certara Reports First Quarter 2022 Financial Results

  5/5/2022

  Certara, Inc., a global leader in biosimulation, reported its financial results for the first quarter of fiscal year 2022.

• Certara to Participate in Upcoming Investor Conferences in May 2022

  5/3/2022

  Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the following investor conferences.

• Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

  4/20/2022

  Certara, Inc. today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022.

• Certara Reports Fourth Quarter and Full Year 2021 Financial Results

  3/1/2022

  Certara, Inc., a global leader in biosimulation, reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022.

• U.S. FDA Licenses Certara’s Immunogenicity SimulatorAffirms the advancements of innovative biosimulation technology and its growing impact in R&D

  2/23/2022

  Certara, Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics. Certara’s IG Simulator predicts the immune response of therapeutics in development, which is important to guide clinical and regulatory decision-making.   

• Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

  2/15/2022

  Certara, Inc., a global leader in biosimulation, announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Review were received by Certara’s customers in 2021, excluding diagnostic agents.

• Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022

  2/8/2022

  Certara, Inc., a global leader in biosimulation, announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Tuesday, March 1st, 2022.

• Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory SubmissionsFDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and offices

  12/21/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and expanded its licenses of Certara’s proprietary biosimulation software, with more than 400 user licenses of Simcyp and Phoenix software.

• Certara Announces Release of Pinnacle 21 Enterprise SoftwareNew metrics and analytics capabilities enable informed decision making for biopharmaceutical clients

  12/13/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates the Company’s flagship software for preparing clinical trial data for biosimulation and regulatory submission.

• Certara to Host Investor Day on December 15, 2021

  12/8/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City.

• Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Recent Regulatory GuidancesSimcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs

  12/2/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 21, which updates the Company’s population-based modeling and simulation platform.

• Certara Announces Update of D360™ Scientific Informatics SoftwareNew capabilities increase efficiency in analyzing and developing small molecules and biologic drugs

  11/29/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of D360 version 21.5, an industry-leading scientific informatics software for discovery scientists to integrate many data sources and analyze small molecules and biologic drugs for fast, high-confidence go/no-go decisions.

• Certara Announces Closing of Public Offering of Common Stock - Nov 22, 2021

  11/22/2021

  Certara, Inc., a global leader in biosimulation, announced the closing of its underwritten public offering of 10,000,000 shares of its common stock by certain existing stockholders at a public offering price of $31.00 per share.

• Certara Announces Pricing of Public Offering of Common Stock - Nov 18, 2021

  11/18/2021

  Certara, Inc., a global leader in biosimulation, announced the pricing of its underwritten public offering of 10 million shares of its common stock by certain existing stockholders at a price to the public of $31.00 per share.

• Certara Announces Proposed Public Offering of Common Stock - Nov 15, 2021

  11/15/2021

  Certara, Inc., a global leader in biosimulation, announced a proposed underwritten public offering by certain selling stockholders of 10 million shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission.

• Certara Reports Third Quarter 2021 Financial Results

  11/9/2021

  Certara, Inc., a global leader in biosimulation, reported its financial results for the third quarter of fiscal year 2021.

• Certara Appoints James E. Cashman III as Chairman of Board of Directors

  11/8/2021

  Certara, Inc., a global leader in biosimulation, announced that James E. Cashman III, a current Board member, will be appointed Chairman of the Board of Directors, effective as of December 1, 2021.

• Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/3/2021

  Certara, Inc. today announced that William F. Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 AwardBiosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category

  10/25/2021

  Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in science and technology” in the past year.